The aims of this study were to determine: (1) whether vasoactive in'/> Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BKCa channels and inhibition of neurotransmitter release
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BKCa channels and inhibition of neurotransmitter release
【2h】

Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BKCa channels and inhibition of neurotransmitter release

机译:雪貂气管粘液分泌的血管活性肠肽(VIP)对神经的调节:BKCa通道的激活和神经递质释放的抑制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">The aims of this study were to determine: (1) whether vasoactive intestinal peptide (VIP) regulates cholinergic and ‘sensory-efferent' (tachykininergic) 35SO4 labelled mucus output in ferret trachea in vitro, using a VIP antibody, (2) the class of potassium (K+) channel involved in VIP-regulation of cholinergic neural secretion using glibenclamide (an ATP-sensitive K+ (KATP) channel inhibitor), iberiotoxin (a large conductance calcium activated K+ (BKca) channel blocker), and apamin (a small conductance Kca (SKca) channel blocker), and (3) the effect of VIP on cholinergic neurotransmission using [3H]-choline overflow as a marker for acetylcholine (ACh) release.Exogenous VIP (1 and 10 μM) alone increased 35SO4 output by up to 53% above baseline, but suppressed (by up to 80% at 1 μM) cholinergic and tachykininergic neural secretion without altering secretion induced by ACh or substance P (1 μM each). Endogenous VIP accounted for the minor increase in non-adrenergic, non-cholinergic (NANC), non-tachykininergic neural secretion, which was compatible with the secretory response of exogenous VIP.Iberiotoxin (3 μM), but not apamin (1 μM) or glibenclamide (0.1 μM), reversed the inhibition by VIP (10 nM) of cholinergic neural secretion.Both endogenous VIP (by use of the VIP antibody; 1 : 500 dilution) and exogenous VIP (0.1 μM), the latter by 34%, inhibited ACh release from cholinergic nerve terminals and this suppression was completely reversed by iberiotoxin (0.1 μM).We conclude that, in ferret trachea in vitro, endogenous VIP has dual activity whereby its small direct stimulatory action on mucus secretion is secondary to its marked regulation of cholinergic and tachykininergic neurogenic mucus secretion. Regulation is via inhibition of neurotransmitter release, consequent upon opening of BKCa channels. In the context of neurogenic mucus secretion, we propose that VIP joins NO as a neurotransmitter of i-NANC nerves in ferret trachea.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 这项研究的目的是确定:(1)血管活性肠肽(VIP)是否在体外调节雪貂气管中胆碱能和'感觉有效'(速激肽能) 35 SO4标记的粘液输出。 VIP抗体,(2)使用格列本脲(ATP敏感性K + (KATP)参与胆碱能神经分泌VIP调节的钾(K + )通道类别通道抑制剂),埃博毒素(大电导钙激活的K + (BKca)通道阻滞剂)和阿帕明(小电导Kca(SKca)通道阻滞剂),以及(3)VIP对[ 3 H]-胆碱溢流作为乙酰胆碱(ACh)释放的标志物进行胆碱能神经传递。 仅外源VIP(1和10μm)增加 35 SO4产量比基准高出多达53%,但受到抑制(最高可达80%a t 1μM)胆碱能和速激肽能神经分泌,而不会改变ACh或P物质(每个1μM)诱导的分泌。内源性VIP占非肾上腺素,非胆碱能(NANC),非速激肽能神经分泌的少量增加,与外源VIP的分泌反应相适应。 伊贝毒素(3μM),但而不是apamin(1μM)或glibenclamide(0.1μM)会逆转VIP(10 nM)对胆碱能神经分泌的抑制作用。 两种内源VIP(通过使用VIP抗体; 1:500稀释液)而外源VIP(0.1μM)抑制了胆碱能神经末梢ACh的释放,后者的抑制作用为34%,而这种毒素被iberiotoxin(0.1μM)完全抵消了。 我们的结论是,在雪貂气管中,内源性VIP具有双重活性,因此其对粘液分泌的小的直接刺激作用是继其对胆碱能和速激肽能神经源性粘液分泌的显着调节之后的。调节是通过抑制神经递质释放来实现的,因此是在BKCa通道打开后进行的。在神经源性粘液分泌的背景下,我们建议VIP加入NO作为雪貂气管i-NANC神经的神经递质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号